English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Copyright © 2016, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Analysis populations • PK population: Patients who received 1 full dose of study drug and had blood samples with quantifiable plasma levels at the Cmax (1 hour after start of infusion) and at least 2 time points after Cmax • Safety population: Patients who received any dose (including partial dose) of study drug

Pharmacokinetics and Safety of Ceftolozane/Tazobactam in Adolescents and Young Children with Proven or Suspected Gram-negative Infection